Adding Strattera to Current ADHD Regimen
Adding Strattera (atomoxetine) to Adderall is generally not recommended as a first-line approach, but could be considered if the patient has inadequate response to Adderall alone, particularly given the complex psychiatric comorbidities present. 1
Key Considerations for This Clinical Scenario
Current Treatment Context
The patient is already on:
- Adderall (amphetamine) - a first-line stimulant for ADHD
- Divalproex - mood stabilizer (likely for mood/bipolar symptoms)
- Trazodone - for sleep/depression
- Bupropion - antidepressant with some ADHD benefit
This represents significant polypharmacy with overlapping psychiatric indications.
Evidence on Combination Therapy
Limited support exists for stimulant + atomoxetine combinations. The research shows mixed results:
- A 2021 systematic review found only 4 studies adding atomoxetine to stimulants, with mixed reports of benefit 2
- The only small RCT showed no benefit from the combination 2
- A 2013 review concluded evidence is "limited" with heterogeneous designs and small samples, noting the combination "may benefit some, but not all patients" 3
- Combinations frequently yielded more side effects, making monotherapy preferable if sufficient response can be achieved 2
When Atomoxetine Makes Sense
Atomoxetine would be more appropriate as:
Switch strategy rather than addition: If Adderall provides inadequate response or intolerable side effects, switching to atomoxetine is evidence-based 1
Specific comorbidity considerations where atomoxetine may be preferred:
"Around-the-clock" coverage: Atomoxetine provides 24-hour symptom control vs. stimulant wear-off 1
Critical Safety Concerns
FDA Black Box Warning: Atomoxetine carries a suicidal ideation risk in children/adolescents (0.4% vs 0% placebo) 6. Given this patient is already on multiple psychiatric medications including antidepressants, close monitoring for:
- Suicidal thoughts/behaviors
- Clinical worsening
- Unusual behavioral changes
is mandatory if atomoxetine is added 6.
Additional monitoring required:
- Liver function (risk of severe hepatotoxicity) 6
- Blood pressure and heart rate (increases both) 6
- Cardiovascular assessment before starting 6
Drug Interaction Concerns
The patient's bupropion may interact with atomoxetine as both affect norepinephrine reuptake, potentially increasing side effects (hypertension, agitation, insomnia).
Practical Algorithm
If ADHD symptoms are inadequately controlled on current Adderall:
- First: Optimize Adderall dose and formulation (consider long-acting if not already)
- Second: Consider switching to lisdexamfetamine (preferred over adding atomoxetine) 1
- Third: If stimulants fail after adequate trials, switch to atomoxetine monotherapy rather than combining 1
- Last resort: Consider adding atomoxetine to stimulant only if:
- Multiple stimulant trials have failed
- Specific residual symptoms persist (evening/morning coverage)
- Patient accepts increased side effect risk
- Close monitoring is feasible
If considering combination therapy specifically:
- Start atomoxetine at low dose (40 mg/day in adults)
- Expect 6-12 weeks for full effect 1, 7
- Monitor weekly initially for psychiatric symptoms
- Check liver enzymes and vital signs regularly
Bottom Line
The evidence does not strongly support adding atomoxetine to an existing stimulant regimen. Given this patient's complex medication profile with mood stabilizers and antidepressants, the risk-benefit ratio favors either optimizing the current Adderall regimen or switching medications rather than adding atomoxetine. If ADHD symptoms remain inadequately controlled despite optimized stimulant therapy, atomoxetine as monotherapy (after tapering Adderall) would be more evidence-based than combination therapy 1, 2.